Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28266625 | 0.88 | MME (0.50) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL17770755 | 0.88 | MME (0.50) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL19696456 | 0.88 | MME (0.50) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL31447099 | 0.86 | MME (0.46) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL23408883 | 0.83 | MME (0.71) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL9830454 | 0.83 | ALDH1A1 (0.64) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL31444803 | 0.83 | MME (0.43) | MMEALDH1A1ACELMNAFOLH1 | |
| SCHEMBL16330769 | 0.83 | CA2 (0.56) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL7331518 | 0.83 | ALDH1A1 (0.64) | MMEALDH1A1ACELMNAMEN1 | |
| SCHEMBL16850468 | 0.83 | ALDH1A1 (0.64) | MMEALDH1A1ACELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-10023555-B2 | NSAIDs derivatives and uses thereof | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2017-09-14 | — | — | US | disclosed |
| US-9688607-B2 | No- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | CYPRUS UNIVERSITY OF TECHNOLOGY (CY) | 2017-06-22 | — | — | US | disclosed |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | PTGS1, NOS2, NOS1 | MME 4044/4885ALDH1A1 363/4885ACE 4263/4885 |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | NOS2, NOS3, NOS1 | MME 4219/4885ALDH1A1 961/4885ACE 4782/4885 |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | MME 1647/4885ALDH1A1 96/4885ACE 3248/4885 |
| US-10023555-B2 | NSAIDs derivatives and uses thereof | PTGES, PTGES3, PTGS1 | MME 1351/4885ALDH1A1 383/4885ACE 904/4885 |
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | PTGES, PTGES3, PTGS1 | MME 1351/4885ALDH1A1 383/4885ACE 904/4885 |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | NOS2, NOS1, HSF1 | MME 3407/4885ALDH1A1 3155/4885ACE 2132/4885 |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | MME 1647/4885ALDH1A1 96/4885ACE 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.